Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Exelixis (EXEL) stock in plain English

Free brief · no signupStart here
EXELPublished Nov 9, 2026
Exelixis Inc
Healthcare · Biotechnology
Sells targeted oncology medicines, primarily cabozantinib formulations, to treat kidney, liver, and thyroid cancers.
Assets:
Alameda campusHouses research laboratories and commercial headquarters in California
Cabometyx franchisePrimary commercial oral cancer medicine sold globally
Cometriq product lineCapsule formulation approved for progressive thyroid cancer
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

90
OPS ScoreOperating finances
Latest quote
-3.60%$65.83
$16.06B
19.7×
$2.50B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 09, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was EXEL. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Exelixis (EXEL) do?

Exelixis Inc (EXEL) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Sells targeted oncology medicines, primarily cabozantinib formulations, to treat kidney, liver, and thyroid cancers. It generates almost all its revenue from commercializing a single oncology drug across multiple cancer indications. It is worth $16.06B on the market and sold $2.50B over the last year.

Market cap
$16.06B
P/E ratio
19.7×
Annual sales
$2.50B
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 09, 2026

Brands and businesses behind EXEL

  • Cabometyx: It is an oral prescription tablet that treats advanced kidney, liver, and thyroid cancers, generating direct product sales.
  • Cometriq: It is an oral capsule treatment for progressive medullary thyroid cancer that generates direct pharmaceutical prescription revenue.

EXEL’s flags, in plain English

Each flag is a number from Exelixis’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 09, 2026.

Low debt

Low debt, only 9% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Fat Margins

Profit margin of 35.5%. The company keeps a healthy share of each sale as profit, which gives it room when costs jump.

Wide Gross Margin

Gross margin of 96.3% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Heavily Shorted

10.8% of tradable shares are bet against (sold short). A large share of the stock has been borrowed and sold by traders betting it will fall. That can be a warning, and it can also push the price up fast if they rush to buy it back.

2 more green flags open with the free trial. Try it free for 7 days.

Questions about EXEL

How big is Exelixis?

Exelixis’ market cap is $16.06B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $2.50B: what customers paid the company over the last year, before any costs.

What is EXEL’s P/E ratio?

EXEL’s P/E ratio is 19.7×. Investors pay about 19.7 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with EXEL?

The company relies on a single compound, cabozantinib, for nearly all of its commercial product revenue. That is one risk on Exelixis’ card. Its first risk flag is Heavily Shorted, explained above. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Exelixis’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. EXEL’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card